Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12403870 | 0.80 | RAB9A (0.42) | RAB9AGAANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21790489 | 0.80 | KMT2A (0.46) | GAASMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL18893410 | 0.74 | GAA (0.44) | RAB9AGAANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3319344 | 0.74 | GAA (0.47) | RAB9AGAANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21790490 | 0.74 | PSIP1 (0.44) | RAB9AGAANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19987450 | 0.73 | KIF11 (0.49) | KIF11ALDH1A1 | |
| SCHEMBL3117689 | 0.71 | RAB9A (0.45) | RAB9AGAANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21790800 | 0.70 | KMT2A (0.43) | RAB9AGAANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21790748 | 0.70 | TAS1R3 (0.40) | RAB9ALMNA | |
| SCHEMBL20156691 | 0.70 | TSHR (0.47) | GAASMN1; SMN2ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | KIF11 2819/4885RAB9A 3778/4885GAA 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.